Literature DB >> 19039753

Drug-induced QRS morphology and duration changes.

John E Madias1.   

Abstract

Drug-induced ECG changes may affect all components of the ECG curve. The attention of regulatory agencies, researchers and clinicians has been directed towards drug-induced QT-interval prolongation and its well-documented proarrhythmia. This presentation focuses on druginduced changes, i.e., morphology, amplitude and QRS complex duration (QRSd). A great variety of pharmacological agents (e.g., class IA and IC antiarrhythmics, antihistamines, antidepressants, antipsychotics) exert an influence on the QRSd. The QRSd is assessed by a variety of ECG methodologies. Standardization of measurements of QRSd ensures the comparability of results by different ECG modalities, and of serial QRSd assessments. Some analgesics and hypoglycemic agents influence the amplitude of QRS complexes by way of their propensity to cause peripheral oedema (extracardiac mechanism). Perhaps a new culture could evolve in which the entire ECG curve, from the onset of the P-wave to the offset of the U-wave, will be used in the evaluation and monitoring of drug safety, with emphasis primarily on the standard ECG.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19039753

Source DB:  PubMed          Journal:  Cardiol J        ISSN: 1898-018X            Impact factor:   2.737


  6 in total

1.  On the relationship between block of the cardiac Na⁺ channel and drug-induced prolongation of the QRS complex.

Authors:  A R Harmer; J-P Valentin; C E Pollard
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

2.  Obesity and hypertension contribute to prolong QRS complex duration among middle-aged adults.

Authors:  Dillon J Dzikowicz; Mary G Carey
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-05-29       Impact factor: 1.468

3.  Remodeling of the 12-lead electrocardiogram in immediate survivors of sudden cardiac arrest.

Authors:  Elizabeth P Held; Kyndaron Reinier; Audrey Uy-Evanado; Kotoka Nakamura; Harpriya S Chugh; Jonathan Jui; Sumeet S Chugh
Journal:  Resuscitation       Date:  2020-06-20       Impact factor: 5.262

4.  False Negative ECG Device Results May Increase the Risk of Adverse Events in Clinical Oncology Trials.

Authors:  Luc Dekie; Robert B Kleiman
Journal:  Ther Innov Regul Sci       Date:  2022-04-26       Impact factor: 1.337

5.  Investigation of connexin 43 uncoupling and prolongation of the cardiac QRS complex in preclinical and marketed drugs.

Authors:  M P Burnham; P M Sharpe; C Garner; R Hughes; C E Pollard; J Bowes
Journal:  Br J Pharmacol       Date:  2014-08-13       Impact factor: 8.739

6.  Cardiac sodium channel inhibition by lamotrigine: In vitro characterization and clinical implications.

Authors:  Lindsey Ingleby-Talecki; Sven C van Dijkman; Sean P Oosterholt; Oscar Della Pasqua; Christina Winter; Marianne Cunnington; Linda Rebar; Sergio Forero-Schwanhaeuser; Vickas Patel; James A Cooper; Anthony Bahinski; Khuram W Chaudhary
Journal:  Clin Transl Sci       Date:  2022-05-31       Impact factor: 4.438

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.